source
- Novo Nordisk sues Eli Lilly over allegedly deceptive obesity and diabetes adsNovo Nordisk has filed a federal lawsuit against Eli Lilly, accusing the rival of running misleading advertisements for its obesity and diabetes medicines. The company claims Lilly's ads rely on ou…
- FDA’s 505(b)(2) pathway offers faster, cheaper drug development and commercial gainsThe FDA’s 505(b)(2) regulatory route lets drug sponsors build on existing safety and efficacy data while proposing meaningful changes to a known product. By leveraging prior findings, companies can…